Market closedNon-fractional
NovoCure/NVCR
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About NovoCure
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Ticker
NVCR
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
Saint Helier, Jersey
Employees
1,453
Website
www.novocure.com
NovoCure Metrics
BasicAdvanced
$1.8B
Market cap
-
P/E ratio
-$1.81
EPS
0.78
Beta
-
Dividend rate
Price and volume
Market cap
$1.8B
Beta
0.78
Financial strength
Current ratio
6.258
Quick ratio
5.971
Long term debt to equity
165.647
Total debt to equity
165.647
Interest coverage (TTM)
-61.89%
Management effectiveness
Return on assets (TTM)
-11.18%
Return on equity (TTM)
-48.70%
Valuation
Price to revenue (TTM)
3.43
Price to book
5.03
Price to tangible book (TTM)
5.03
Price to free cash flow (TTM)
-14.89
Growth
Revenue change (TTM)
0.61%
Earnings per share change (TTM)
34.84%
3-year revenue growth
-0.10%
3-year earnings per share growth
159.22%
What the Analysts think about NovoCure
Analyst Ratings
Majority rating from 7 analysts.
NovoCure Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$139M
3.59%
Net income
-$39M
-17.66%
Profit margin
-27.94%
-20.51%
NovoCure Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.54
-$0.46
-$0.45
-$0.36
-
Expected
-$0.50
-$0.53
-$0.52
-$0.42
-$0.42
Surprise
7.91%
-12.38%
-13.70%
-14.84%
-
NovoCure News
AllArticlesVideos
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
Business Wire·1 month ago
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
Business Wire·2 months ago
Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NovoCure stock?
NovoCure (NVCR) has a market cap of $1.8B as of July 05, 2024.
What is the P/E ratio for NovoCure stock?
The price to earnings (P/E) ratio for NovoCure (NVCR) stock is 0 as of July 05, 2024.
Does NovoCure stock pay dividends?
No, NovoCure (NVCR) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next NovoCure dividend payment date?
NovoCure (NVCR) stock does not pay dividends to its shareholders.
What is the beta indicator for NovoCure?
NovoCure (NVCR) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell NovoCure stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.